The body's growth hormone system operates through a carefully regulated feedback loop. The hypothalamus releases GHRH (growth hormone-releasing hormone) in pulses, which signals the pituitary to release GH into the bloodstream. GH then stimulates the liver to produce IGF-1, which carries out most of GH's tissue-building effects.
GH secretagogue peptides mimic and amplify this natural cascade. CJC-1295 is a long-acting GHRH analog — it extends the natural GHRH pulse. Ipamorelin is a ghrelin receptor agonist — it provides a second, complementary signal to the pituitary. Together they produce GH releases 3–5x higher than baseline while preserving the natural pulsatile pattern.
The CJC-1295 + Ipamorelin combination is the most commonly prescribed GH peptide stack because it uses two different receptor mechanisms simultaneously — like pushing two accelerator pedals at once — for synergistic GH release that far exceeds either peptide alone.
Unlike direct HGH injection, secretagogue peptides allow the pituitary's feedback systems to remain intact — if GH levels rise too high, the body's natural inhibitory mechanisms engage. This built-in safety feature makes secretagogues the preferred approach for most patients.